Chinese authorities allowed Sinocelltech (SHA:688520) subsidiary Beijing Sinocell Biotechnology to conduct clinical trials for the SCTB39G injection for advanced solid tumors, according to a Thursday filing with the Shanghai bourse.
The injection is a multi-target immunotherapy trispecific antibody injection, the filing said.
Shares in the drug company slipped 2% during morning trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments